Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab

This publication has 25 references indexed in Scilit:

• Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
  Hematological Oncology, 2025
• The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
  Cancer Immunology, Immunotherapy, 2024
• Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
  Cancer Immunology, Immunotherapy, 2023
• Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions
  Current Treatment Options in Oncology, 2023
• Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
  Scientific Reports, 2023
• Distribution and reference interval establishment of neutral‐to‐lymphocyte ratio (NLR), lymphocyte‐to‐monocyte ratio (LMR), and platelet‐to‐lymphocyte ratio (PLR) in Chinese healthy adults
  Journal of Clinical Laboratory Analysis, 2021
• Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome
  JAMA Dermatology, 2021
• Graphical calibration curves and the integrated calibration index (ICI) for survival models
  Statistics in Medicine, 2020
• Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
  Lung Cancer, 2018
• Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
  Bone Marrow Transplantation, 2012